Investment Rating - The report maintains a "Buy" rating for the company, with expected revenue growth and profitability improvements in the coming years [5]. Core Views - The company reported a revenue of 1.44 billion RMB for FY24, a year-over-year decrease of 2.78%, but showed signs of recovery with a 6.06% increase in Q1 2025 [2]. - The net profit for FY24 was a loss of 163 million RMB, primarily due to goodwill impairment of 59.06 million RMB, indicating challenges in profitability [2]. - The gross margin for FY24 was 93.22%, slightly down from the previous year, attributed to rising costs in AI server operations [2]. Revenue and Profit Analysis - FY24 revenue breakdown shows video creative products generated 961 million RMB, a slight increase of 0.06%, while practical tools and document creative categories saw declines of 8.70% and 10.13% respectively [3]. - International revenue accounted for 90.51% of total revenue, amounting to 1.30 billion RMB, with a year-over-year decrease of 3.51% [3]. Expense Structure - The company increased its R&D, sales, and management expense ratios to 30.72%, 58.94%, and 11.40% respectively in FY24, indicating a strategic focus on growth despite the losses [4]. - In Q1 2025, the sales expense ratio rose significantly to 62.78%, reflecting increased investment in sales efforts [4]. Future Projections - Revenue forecasts for 2025 to 2027 are set at 1.68 billion RMB, 1.97 billion RMB, and 2.36 billion RMB respectively, with expected net profits turning positive in 2025 [5]. - The projected price-to-sales (P/S) ratios for the next three years are approximately 6.3, 5.4, and 4.5 times, indicating a favorable valuation trend [5].

事件 4 月 28 日公司发布 2024 年报及 2025 年一季报，2024 年实现营收 30.27 亿元，同比-24.09%；归母净利润为-2.87 亿元，同比亏损。 4Q24 收入为 10.75 亿元，环比+34.65%、同比+21.83%；归母净利 润为-0.84 亿元，环比、同比亏损。1Q25 实现收入 7.28 亿元，环 比-32.28%、同比+141.32%；归母净利润为 0.73 亿元，环比、同 比均扭亏。 点评 价格上涨，1Q25 业绩符合预期。1Q25 氧化镨钕、氧化镝、氧化铽 价格环比分别+3.29%/-0.86%/+6.79%,公司主营产品价格整体上 行；销量方面，2024 年公司稀土氧化物生产量较上年同期提升 107.27%；基于公司现有产能释放情况，我们认为 1Q25 公司产品 销量同比有所增长。1Q25 公司毛利、毛利率分别同比+446.15%、 +5.45pct 至 0.71 亿元、9.75%。 期间费率保持平稳，研发保持高投入。1Q25 公司期间费用环比 -31.91%至 0.32 亿元;期间费率环比+0.02pct 至 4.40%、同比 -2.89pct 至 4.40% ； ...

事件 4 月 27 日公司发布 2025 年一季报，实现营收 17.54 亿元，环比 +0.29%、同比+14.19%；归母净利润为 1.61 亿元，环比+70.48%、 同比+57.85%；扣非归母净利润为 1.06 亿元，环比+30.70%、同比 +331.10%。 点评 量价齐升，业绩超预期。1Q25 氧化镨钕和钕铁硼市场均价分别环 比+3.29%、+1.60%至 42.96 万元/吨和 201 元/公斤；销量显著增 长，1Q25 公司磁材成品产量约 0.66 万吨，磁材成品销量约 0.6 万 吨，较上年同期均增长超 40%。量价齐升带来盈利能力显著改 善,1Q25 公司毛利率环比+1.44pct 至 15.68%，毛利环比+10.44%至 2.75 亿元。考虑公司生产经营的季节性，1Q25 业绩超预期。 整体费用控制良好，研发费用保持增长。1Q25 公司期间费用环比 -10.97% 至 1.38 亿 元 ，期间费率分别环比、同比 - 0.99pct/+0.58pct；其中销售费率环比-0.40pct 至 1.03%,财务费 率环比+0.06pct 至-0.68%。公司仍然保持高水平研发投入，1Q25 ...

业绩简评 2025 年 4 月 27 日公司披露 24 年报，24 年实现营收 12.22 亿元， 同比增长 20.98%，市场份额稳居本土 EDA 企业首位；归母净利润 1.09 亿元，同比下降 45.46%；扣非归母净利润亏损 0.57 亿元。 单 Q4 公司实现营收 4.79 亿元，同比增长 29.13%；实现归母净利 润 0.51 亿元，同比增长 73.71%。 经营分析 分业务来看，24 年公司 EDA 软件销售营收为 10.92 亿元，同比增 长 20.71%；技术服务业务营收为 1.15 亿元，同比增长 40.01%； 硬件、代理软件销售及其他收入 0.15 亿元，同比下降 35.71%。公 司境外收入占比为 4.72%，收入同比下降 13.32%。 成本费用方面，24 年公司毛利率为 93.31%，较上年同期下降 0.48pct。公司剔除股份支付费用后的销售/管理/研发费用率分别 为 16.31%/12.05%/60.79% ， 分 别 同 比 下 降 0.03pct/0.57pct/6.61pct。截至 24 年末公司共有员工 1,202 人， 同比增加 17.50%，其中销售/技术人员同比 ...

业绩简评 2025 年 4 月 25 日公司披露 24 年年报及 25 年一季报，2024 年公 司实现营收 272 亿元，同比下降 3.4%；实现归母净利润 3.46 亿 元，同比下降 8.1%。2025 年一季度公司实现收入 77.0 亿元，同 比增长 51.8%，实现归母净利润 3.0 亿元，同比下降 0.7%。 经营分析 风机制造及发电业务盈利承压，电站销售转让保持增长：2024 年 公司风机及相关配件销售实现收入 208.3 亿元，同比下降 12.4%， 实现毛利率-0.46%，同比下降 3.6%，预计主要受海风推进受阻， 交付不及预期影响，2025 年公司前期中标的广东多个重要海风项 目陆续开始施工，项目确收有望逐步加速。发电收入同比增长 15.4%，但毛利率同比下降 5.86pct 至 57.1%，预计主要受部分地 区新能源市场化交易推进，上网电价有一定下降影响。电站销售转 让保持增长，2024 年公司电站产品销售实现收入约 27.9 亿元，同 比+34.2%，毛利率同比提升 12.2pct 至 43.2%，同时实现投资收益 11.6 亿元，同比提升 38%。 Q1 交付加速，规模效应体现明显： ...

业绩简评 2025 年 4 月 27 日公司披露 24 年报，24 年实现营收 12.22 亿元， 同比增长 20.98%，市场份额稳居本土 EDA 企业首位；归母净利润 1.09 亿元，同比下降 45.46%；扣非归母净利润亏损 0.57 亿元。 单 Q4 公司实现营收 4.79 亿元，同比增长 29.13%；实现归母净利 润 0.51 亿元，同比增长 73.71%。 分业务来看，24 年公司 EDA 软件销售营收为 10.92 亿元，同比增 长 20.71%；技术服务业务营收为 1.15 亿元，同比增长 40.01%； 硬件、代理软件销售及其他收入 0.15 亿元，同比下降 35.71%。公 司境外收入占比为 4.72%，收入同比下降 13.32%。 成本费用方面，24 年公司毛利率为 93.31%，较上年同期下降 0.48pct。公司剔除股份支付费用后的销售/管理/研发费用率分别 为 16.31%/12.05%/60.79% ， 分 别 同 比 下 降 0.03pct/0.57pct/6.61pct。截至 24 年末公司共有员工 1,202 人， 同比增加 17.50%，其中销售/技术人员同比增长 17 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenue reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is projected to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenues reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is forecasted to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company [4][9] Core Views - The company experienced short-term performance pressure but is actively expanding its overseas market, which is expected to create new growth points in the electric meter and energy storage businesses [2][3] - In 2024, the company achieved an operating income of 6.742 billion RMB, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 753 million RMB, down 27% year-on-year [2][8] - The overseas revenue reached 1.126 billion RMB in 2024, marking a 34% year-on-year increase, indicating successful market expansion efforts [3] Summary by Sections Performance Overview - In 2024, the company reported an operating income of 6.742 billion RMB, a decrease of 1.89% from the previous year, and a net profit of 753 million RMB, down 27% year-on-year [2][8] - The first quarter of 2025 saw an operating income of 1.124 billion RMB, a 27% decline year-on-year, with a net profit of 124 million RMB, down 43% [2] Business Analysis - The company is focusing on overseas market expansion, with a significant partnership with global meter leader Landis+Gyr to increase market share in Western Europe and Asia-Pacific [3] - The energy storage segment generated 920 million RMB in revenue in 2024, a 39% decline, but maintained a gross margin of 17.64%, an increase of 1.55 percentage points year-on-year [3] - The company’s power station construction is progressing steadily, with power station revenue of 1.19 billion RMB in 2024, down 8%, but with a gross margin of 25.94%, up 14.46 percentage points year-on-year [3] Profit Forecast and Valuation - The projected net profits for 2025, 2026, and 2027 are 850 million RMB, 970 million RMB, and 1.1 billion RMB, respectively, with corresponding price-to-earnings ratios of 15, 13, and 12 times [4][8]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company reported a revenue of 831 million RMB for 2024, a decrease of 1.77% year-on-year, and a net profit attributable to shareholders of 144 million RMB, down 36.89% year-on-year. For Q1 2025, revenue was 239 million RMB, an increase of 8.85%, while net profit was 31 million RMB, down 26.99% year-on-year [2] - The company is experiencing a gradual recovery in operations, with revenue growth turning positive in Q4 2024 and Q1 2025. The company is strengthening its position in the outdoor equipment manufacturing sector while increasing investment in new product development [3] - The company is expanding its international market presence, having established partnerships with new brand clients in Australia and North America, with some products already in mass production [3] Summary by Sections Performance Review - For 2024, the company expects to distribute cash dividends of 67.53 million RMB, with a dividend payout ratio of approximately 52% [2] Operational Analysis - Revenue from tents, sleeping bags, clothing, and backpacks for 2024 was 361 million, 117 million, 256 million, and 39 million RMB respectively, with year-on-year changes of -22.33%, -2.29%, +41.73%, and -4.61% [3] - The company aims to deepen customer relationships and expand its high-potential customer base while introducing high-performance materials into its product lines [4] Financial Forecast and Valuation - The company is projected to have EPS of 2.36, 2.60, and 2.88 RMB for 2025-2027, corresponding to PE ratios of 15, 14, and 12 times [5] - The company’s revenue is expected to grow to 936 million RMB in 2025, with a growth rate of 12.68% [10]